NCT02207309 2024-08-09
Pazopanib Maintenance Phase II
Ludwig-Maximilians - University of Munich
Phase 2 Terminated
Clinical Trials
11 trialsNCT02212015 2022-03-22
EVA
Heidelberg University
Phase 2 Terminated
NCT01759303 2021-04-13
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Emerald Clinical Inc.
Phase 2 Terminated
NCT01543802 2021-01-26
NOPASS
Heidelberg University
Phase 2 Terminated
NCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT02795819 2019-10-24
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
Phase 1 Terminated
NCT01418001 2018-01-11
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT01012362 2017-12-28
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT02113826 2017-11-06
Pazopanib for Metastatic Alveolar Soft Part Sarcoma
Seoul National University Hospital
Phase 2 Terminated
NCT01391611 2017-04-07
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Stanford University
Phase 2 Terminated
NCT01059656 2016-07-01
DFSP-PAZO
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated